JOP20090061B1 - طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH - Google Patents
طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRHInfo
- Publication number
- JOP20090061B1 JOP20090061B1 JOP/2009/0061A JOP20090061A JOP20090061B1 JO P20090061 B1 JOP20090061 B1 JO P20090061B1 JO P20090061 A JOP20090061 A JO P20090061A JO P20090061 B1 JOP20090061 B1 JO P20090061B1
- Authority
- JO
- Jordan
- Prior art keywords
- prostate cancer
- methods
- treating prostate
- gnrh antagonist
- gnrh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
يتعلق الاختراع الحالي بتوفير استخدامات وأنظمة جرعة خاصة هرمون اطلاق المنشط التناسلي (GnRH) وذلك من اجل اجراءات الامان والمعالجة الفعالة لسرطان البروستاتا المعتمد على الاندروجين وبدون التسبب في ارتفاع حاد في التستوسترون و/او اثار جانبية اخرى خاصة بالمعالجة بمساعد (GnRH) مثل عدوى القناة البولية او الالم المفصلي المرتبط بالتاثير الجانبي القلبي الوعائي. شكل (1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2774108P | 2008-02-11 | 2008-02-11 | |
EP08250703 | 2008-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20090061B1 true JOP20090061B1 (ar) | 2021-08-17 |
Family
ID=39718285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0061A JOP20090061B1 (ar) | 2008-02-11 | 2009-02-09 | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
Country Status (25)
Country | Link |
---|---|
US (15) | US20090203623A1 (ar) |
EP (7) | EP2650012B1 (ar) |
JP (10) | JP5876652B2 (ar) |
KR (7) | KR20230088848A (ar) |
CN (4) | CN101998861A (ar) |
AU (2) | AU2009213751B2 (ar) |
BR (2) | BRPI0908127A2 (ar) |
CA (3) | CA3235099A1 (ar) |
CY (3) | CY1115561T1 (ar) |
DK (3) | DK2249859T3 (ar) |
EA (4) | EA026521B1 (ar) |
ES (3) | ES2479441T3 (ar) |
HK (4) | HK1198243A1 (ar) |
HR (3) | HRP20140665T1 (ar) |
IL (3) | IL207295A (ar) |
JO (1) | JOP20090061B1 (ar) |
MX (2) | MX2010008817A (ar) |
NZ (4) | NZ603932A (ar) |
PL (3) | PL2650012T3 (ar) |
PT (3) | PT2650012E (ar) |
RU (2) | RU2504393C2 (ar) |
SI (3) | SI2505204T1 (ar) |
TW (2) | TWI442932B (ar) |
WO (2) | WO2009101530A1 (ar) |
ZA (1) | ZA201005697B (ar) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
JO3525B1 (ar) * | 2008-02-11 | 2020-07-05 | Ferring Int Center Sa | علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس |
TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
NZ595767A (en) * | 2009-05-01 | 2012-12-21 | Ferring Bv | Composition for the treatment of prostate cancer |
TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
FR2964323B1 (fr) * | 2010-09-08 | 2012-11-09 | Jean Pierre Raynaud | Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate |
ES2617336T3 (es) | 2010-10-27 | 2017-06-16 | Ferring B.V. | Procedimiento para la fabricación de degarelix y sus productos intermedios |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
CN104169425A (zh) | 2011-03-09 | 2014-11-26 | 理查德·G·佩斯泰尔 | 前列腺癌细胞系、遗传标志及其用途 |
CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
US9453836B2 (en) | 2012-05-14 | 2016-09-27 | Richard G. Pestell | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis |
AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
UA117663C2 (uk) | 2012-09-26 | 2018-09-10 | Арагон Фармасьютікалз, Інк. | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози |
US10881659B2 (en) | 2013-03-15 | 2021-01-05 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
WO2014186608A1 (en) * | 2013-05-15 | 2014-11-20 | Adverse Events, Inc. | System and method for surveillance and evaluation of safety risks associated with medical interventions |
EP3185881B1 (en) * | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
CA2984188A1 (en) | 2015-05-12 | 2016-11-17 | Drexel University | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same |
CA3051182A1 (en) * | 2017-01-30 | 2018-08-02 | Finn Larsen | A composition comprising at least one gnrh antagonist |
WO2019203870A1 (en) | 2018-04-19 | 2019-10-24 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
EP3697398A1 (en) | 2017-10-16 | 2020-08-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
WO2020028630A1 (en) * | 2018-08-01 | 2020-02-06 | Abbvie Inc. | Dosing regimens for elagolix |
RU2731002C1 (ru) * | 2019-10-22 | 2020-08-26 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения рака предстательной железы |
CN116407494A (zh) * | 2023-03-02 | 2023-07-11 | 山东大学齐鲁医院 | 一种醋酸地加瑞克注射液及其制备方法、用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4072668A (en) | 1973-11-06 | 1978-02-07 | The Salk Institute For Biological Studies | LH-RH Analogs |
EP0002749B2 (en) | 1977-12-26 | 1987-08-12 | IHARA CHEMICAL INDUSTRY Co., Ltd. | Process for producing aromatic monocarboxylic acid |
US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
DE593491T1 (de) | 1991-04-25 | 1994-11-17 | Romano Deghenghi | LHRH-Antagonisten. |
ATE200428T1 (de) | 1992-02-12 | 2001-04-15 | Daikyo Gomu Seiko Kk | Medizinisches gerät |
GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5825730A (en) | 1995-03-10 | 1998-10-20 | Kabushiki Kaisha Toshiba | Mastering machine having non-repetitive runout compensation |
US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
US5710246A (en) | 1996-03-19 | 1998-01-20 | Abbott Laboratories | Process for intermediates for the synthesis of LHRH antagonists |
US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
AU1590699A (en) | 1997-11-20 | 1999-06-15 | Ortho-Mcneil Pharmaceutical, Inc. | Liquid phase process for the preparation of gnrh peptides |
FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
JP2002521331A (ja) | 1998-07-20 | 2002-07-16 | ペプテック リミテッド | バイオインプラント製剤 |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
MXPA03010804A (es) * | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US20070015713A1 (en) | 2005-07-14 | 2007-01-18 | Voyager Pharmaceutical Corporation | Methods for treating prostate cancer |
US20060234918A1 (en) * | 2001-12-19 | 2006-10-19 | Voyager Pharmaceutical Corporation | Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
SE0104463D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
ME00509B (me) | 2002-09-27 | 2011-10-10 | Zentaris Gmbh | Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje |
GB0223367D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Therapeutic treatment |
AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
WO2006069779A1 (en) | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
WO2009048932A2 (en) | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
WO2009090189A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co.Kg | Powdered protein compositions and methods of making same |
TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
EP2257324B1 (en) * | 2008-02-11 | 2016-07-27 | Safety Syringes, Inc. | Syringe with safety needle guard and clip to prevent release of guard during reconstitution process |
WO2010121835A1 (en) | 2009-04-24 | 2010-10-28 | Polypeptide Laboratories A/S | Method for the manufacture of degarelix |
NZ595767A (en) | 2009-05-01 | 2012-12-21 | Ferring Bv | Composition for the treatment of prostate cancer |
TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
WO2011066386A1 (en) | 2009-11-25 | 2011-06-03 | Novetide, Ltd. | Process for production of degarelix |
ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
ES2617336T3 (es) | 2010-10-27 | 2017-06-16 | Ferring B.V. | Procedimiento para la fabricación de degarelix y sus productos intermedios |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
CN102204889B (zh) | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
DK2731607T3 (en) | 2011-07-15 | 2018-01-02 | Ferring Bv | Method for adjusting the timing of a colonoscopy in which a picosulfate composition is administered. |
AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
-
2009
- 2009-02-09 TW TW098104075A patent/TWI442932B/zh active
- 2009-02-09 TW TW098104073A patent/TWI539959B/zh active
- 2009-02-09 JO JOP/2009/0061A patent/JOP20090061B1/ar active
- 2009-02-10 DK DK09711390.6T patent/DK2249859T3/da active
- 2009-02-10 KR KR1020237019555A patent/KR20230088848A/ko not_active Application Discontinuation
- 2009-02-10 EA EA201300742A patent/EA026521B1/ru not_active IP Right Cessation
- 2009-02-10 US US12/368,935 patent/US20090203623A1/en not_active Abandoned
- 2009-02-10 PL PL13168404T patent/PL2650012T3/pl unknown
- 2009-02-10 KR KR1020147030003A patent/KR20140130757A/ko active Search and Examination
- 2009-02-10 EP EP13168404.5A patent/EP2650012B1/en not_active Revoked
- 2009-02-10 PT PT131684045T patent/PT2650012E/pt unknown
- 2009-02-10 ES ES09711390.6T patent/ES2479441T3/es active Active
- 2009-02-10 BR BRPI0908127-5A patent/BRPI0908127A2/pt not_active Application Discontinuation
- 2009-02-10 KR KR1020157020657A patent/KR20150091543A/ko active Application Filing
- 2009-02-10 PL PL09711390T patent/PL2249859T3/pl unknown
- 2009-02-10 NZ NZ603932A patent/NZ603932A/en unknown
- 2009-02-10 CN CN2009801127793A patent/CN101998861A/zh active Pending
- 2009-02-10 NZ NZ603958A patent/NZ603958A/xx unknown
- 2009-02-10 MX MX2010008817A patent/MX2010008817A/es active IP Right Grant
- 2009-02-10 RU RU2010133481/15A patent/RU2504393C2/ru active
- 2009-02-10 RU RU2010133480/15A patent/RU2504394C2/ru active
- 2009-02-10 KR KR1020107020035A patent/KR101542480B1/ko active IP Right Grant
- 2009-02-10 DK DK13168404.5T patent/DK2650012T3/da active
- 2009-02-10 AU AU2009213751A patent/AU2009213751B2/en active Active
- 2009-02-10 CA CA3235099A patent/CA3235099A1/en active Pending
- 2009-02-10 EA EA201300741A patent/EA036695B1/ru not_active IP Right Cessation
- 2009-02-10 CN CN201410247166.3A patent/CN103990107A/zh active Pending
- 2009-02-10 EP EP09709538A patent/EP2249858A1/en not_active Ceased
- 2009-02-10 PL PL12165896T patent/PL2505204T3/pl unknown
- 2009-02-10 WO PCT/IB2009/000350 patent/WO2009101530A1/en active Application Filing
- 2009-02-10 EA EA200901074A patent/EA017582B1/ru not_active IP Right Cessation
- 2009-02-10 BR BRPI0908129-1A patent/BRPI0908129A2/pt not_active Application Discontinuation
- 2009-02-10 KR KR1020107020036A patent/KR20100123714A/ko active Application Filing
- 2009-02-10 CA CA2714445A patent/CA2714445C/en not_active Expired - Fee Related
- 2009-02-10 KR KR1020227000962A patent/KR20220009504A/ko not_active Application Discontinuation
- 2009-02-10 SI SI200931138T patent/SI2505204T1/sl unknown
- 2009-02-10 CA CA2714444A patent/CA2714444A1/en active Pending
- 2009-02-10 NZ NZ587088A patent/NZ587088A/xx unknown
- 2009-02-10 EP EP12165896.7A patent/EP2505204B1/en not_active Revoked
- 2009-02-10 EA EA200901075A patent/EA020543B1/ru unknown
- 2009-02-10 ES ES13168404.5T patent/ES2540235T3/es active Active
- 2009-02-10 EP EP18151844.0A patent/EP3360565A1/en active Pending
- 2009-02-10 JP JP2010545576A patent/JP5876652B2/ja active Active
- 2009-02-10 JP JP2010545575A patent/JP5924866B2/ja active Active
- 2009-02-10 AU AU2009213748A patent/AU2009213748B9/en active Active
- 2009-02-10 WO PCT/IB2009/000370 patent/WO2009101533A1/en active Application Filing
- 2009-02-10 EP EP23174353.5A patent/EP4257197A3/en active Pending
- 2009-02-10 SI SI200931181T patent/SI2650012T1/sl unknown
- 2009-02-10 PT PT12165896T patent/PT2505204E/pt unknown
- 2009-02-10 MX MX2010008816A patent/MX2010008816A/es active IP Right Grant
- 2009-02-10 US US12/368,713 patent/US8841081B2/en active Active
- 2009-02-10 ES ES12165896.7T patent/ES2532709T3/es active Active
- 2009-02-10 PT PT97113906T patent/PT2249859E/pt unknown
- 2009-02-10 SI SI200930942T patent/SI2249859T1/sl unknown
- 2009-02-10 EP EP09711390.6A patent/EP2249859B1/en not_active Revoked
- 2009-02-10 DK DK12165896T patent/DK2505204T3/da active
- 2009-02-10 NZ NZ587057A patent/NZ587057A/xx unknown
- 2009-02-10 CN CN201710169651.7A patent/CN107412726A/zh active Pending
- 2009-02-10 KR KR1020187030959A patent/KR20180118830A/ko not_active Application Discontinuation
- 2009-02-10 EP EP14170557.4A patent/EP2799085A1/en not_active Ceased
- 2009-02-10 CN CN200980104713XA patent/CN101939020B/zh active Active
-
2010
- 2010-07-29 IL IL207295A patent/IL207295A/en active IP Right Grant
- 2010-08-04 IL IL207400A patent/IL207400A/en active IP Right Grant
- 2010-08-10 ZA ZA2010/05697A patent/ZA201005697B/en unknown
- 2010-12-09 HK HK14111736.0A patent/HK1198243A1/xx unknown
- 2010-12-09 HK HK10111506.2A patent/HK1145011A1/xx unknown
- 2010-12-09 HK HK14103602.8A patent/HK1190912A1/xx unknown
- 2010-12-09 HK HK13103556.5A patent/HK1176552A1/xx not_active IP Right Cessation
-
2012
- 2012-04-27 US US13/458,330 patent/US9415085B2/en active Active
- 2012-11-19 IL IL223124A patent/IL223124A0/en unknown
-
2013
- 2013-12-24 US US14/139,922 patent/US9579359B2/en active Active
-
2014
- 2014-03-14 JP JP2014051197A patent/JP6189234B2/ja active Active
- 2014-04-22 JP JP2014087895A patent/JP6254042B2/ja active Active
- 2014-07-14 HR HRP20140665AT patent/HRP20140665T1/hr unknown
- 2014-07-18 CY CY20141100542T patent/CY1115561T1/el unknown
- 2014-08-08 US US14/454,825 patent/US9877999B2/en active Active
-
2015
- 2015-02-13 CY CY20151100155T patent/CY1116341T1/el unknown
- 2015-03-16 HR HRP20150290AT patent/HRP20150290T1/hr unknown
- 2015-05-14 CY CY20151100434T patent/CY1116289T1/el unknown
- 2015-06-12 HR HRP20150633TT patent/HRP20150633T1/hr unknown
-
2016
- 2016-05-11 JP JP2016095555A patent/JP2016193910A/ja active Pending
- 2016-05-18 JP JP2016099437A patent/JP2016216455A/ja active Pending
- 2016-07-08 US US15/205,108 patent/US10695398B2/en active Active
-
2017
- 2017-01-13 US US15/405,552 patent/US10729739B2/en active Active
- 2017-09-27 JP JP2017185676A patent/JP6618967B2/ja active Active
- 2017-12-18 US US15/845,391 patent/US20190167755A1/en active Pending
-
2020
- 2020-04-17 US US16/851,179 patent/US10973870B2/en active Active
- 2020-05-21 US US16/880,608 patent/US11766468B2/en active Active
-
2021
- 2021-03-12 US US17/199,733 patent/US20220031801A1/en active Pending
-
2022
- 2022-03-31 US US17/710,889 patent/US20220218782A1/en not_active Abandoned
- 2022-03-31 US US17/710,905 patent/US20220218783A1/en not_active Abandoned
- 2022-03-31 US US17/710,899 patent/US11826397B2/en active Active
- 2022-05-31 US US17/829,134 patent/US20220323538A1/en not_active Abandoned
- 2022-07-07 JP JP2022109616A patent/JP7400029B2/ja active Active
- 2022-09-08 JP JP2022142833A patent/JP2022184898A/ja active Pending
-
2023
- 2023-12-06 JP JP2023206150A patent/JP2024028869A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20090061B1 (ar) | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH | |
TN2011000239A1 (en) | Hsp90 inhibitor combinations | |
GB2454118B (en) | Hdac inhibitors and hormone targeted drugs for the treatment of cancer | |
MX2013003594A (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl. | |
MX2010005221A (es) | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. | |
MX349787B (es) | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. | |
AP2012006253A0 (en) | Use of toll-like receptors and agonist for treating cancer. | |
HK1145803A1 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
EP2142125A4 (en) | METHODS, DEVICES AND SYSTEMS FOR NON-INVASIVE ADMINISTRATION OF MICROWAVE THERAPY | |
IN2012DN02046A (ar) | ||
UA104589C2 (ru) | Каннабиноиды в комбинации с неканнабиноидными химиотерапевтическими агентами, например смре или алкилирующими агентами | |
GB2411849B (en) | Apparatus for mixing and discharging bone cement | |
EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
MX351889B (es) | Composiciones y métodos anti-cxcr1. | |
PL2552404T3 (pl) | Pozajelitowa postać leku, która uwalnia inhibitory aromatazy i gestageny, do leczenia endometriozy | |
MY150600A (en) | Use of opioid antagonists for treating urinary retention | |
PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use | |
WO2009108857A3 (en) | Combination therapy for prostate cancer | |
EP2403339A4 (en) | TUMOR COMBINATION THERAPY WITH AN ACT HEMMER AND OTHER ANTUMOURANTS | |
EA201100882A1 (ru) | Профилактическое/терапевтическое средство против рака | |
WO2011101634A3 (en) | Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist | |
TN2011000214A1 (en) | Combination of hsp90 and herceptin inhibitors | |
MX2013003903A (es) | Nuevos tratamientos de infeccion por el virus de hepatitis c. | |
UA43973U (en) | Method for treating osteoarthrosis | |
CL2008001150A1 (es) | Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un inhibidor de la aromatasa; y su uso para el tratamiento de cancer de mama. |